1. Gynecol Endocrinol. 2020 May;36(5):421-425. doi:
10.1080/09513590.2020.1718092.  Epub 2020 Jan 29.

Metformin use is associated with a lower risk of osteoporosis in adult women 
independent of type 2 diabetes mellitus and obesity. REDLINC IX study.

Blümel JE(1), Arteaga E(2), Aedo S(3), Arriola-Montenegro J(4), López M(5), 
Martino M(6), Miranda C(7), Miranda O(8), Mostajo D(9), Ñañez M(10), Ojeda 
E(11), Pilnik S(12), Rojas J(13), Salinas C(14), Sosa L(15), Spritzer PM(16), 
Tserotas K(17), Vallejo MS(18), Belardo A(19), Fighera TM(16), Chedraui 
P(20)(21).

Author information:
(1)Departamento de Medicina Interna Sur, Facultad de Medicina, Universidad de 
Chile, Santiago de Chile, Chile.
(2)Departamento de Endocrinología and CETREN, Facultad de Medicina, Pontificia 
Universidad Católica de Chile, Santiago de Chile, Chile.
(3)Escuela de Medicina, Facultad de Medicina, Universidad Finis Terrae, Santiago 
de Chile, Chile.
(4)Sociedad Nacional de Capacitación (SONACAP), Lima, Perú.
(5)Departamento de Endocrinología, Hospital Militar, Santiago de Chile, Chile.
(6)Red Latinoamericana de Investigación en Climaterio, Rosario, Argentina.
(7)Hospital Central FAP, Lima, Perú.
(8)Facultad de Medicina, Universidad Uniandes, Ambato, Ecuador.
(9)Red Latinoamericana de Investigación en Climaterio, Santa Cruz, Bolivia.
(10)Universidad Nacional de Córdoba, Córdoba, Argentina.
(11)Departamento de Obstetricia y Ginecología, Universidad Andina del Cusco, 
Cusco, Perú.
(12)Hospital Italiano, Buenos Aires, Argentina.
(13)Universidad Peruana Cayetano Heredia, Lima, Perú.
(14)Hospital Ángeles Puebla, Puebla, México.
(15)Hospital Central del Instituto de Previsión Social, Asunción, Paraguay.
(16)Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de 
Clínicas, Porto Alegre, Brazil.
(17)Departamento de Gineco-Obstetricia, Complejo Hospitalario Dr. Arnulfo Arias 
Madrid de la Caja del Seguro Social de Panamá, Ciudad de Panamá, Panamá.
(18)Clínica Quilín, Universidad de Chile, Santiago de Chile, Chile.
(19)Instituto Universitario del Hospital Italiano, Buenos Aires, Argentina.
(20)Facultad de Ciencias Médicas, Instituto de Investigación e Innovación en 
Salud Integral, Universidad Católica de Santiago de Guayaquil, Guayaquil, 
Ecuador.
(21)Facultad de Ciencias de la Salud, Universidad Católica 'Nuestra Señora de la 
Asunción', Asunción, Paraguay.

Metformin may decrease cell senescence, including bone; hence we aimed at 
evaluating the association between metformin use and osteoporosis. This was a 
cross-sectional study carried out in 1259 Latin American adult women aged 40 or 
more who were not on anti-osteoporotic drugs, were on metformin and had a bone 
densitometry performed. Of the whole sample, 40.3% reported being on metformin 
(at least 1 year), 30.2% had type 2 diabetes mellitus and 22.6% had 
osteoporosis. Median (interquartile range) body mass index (BMI) for the whole 
cohort was 27.7 (4.6) kg/m2 and 30.2% had type 2 diabetes mellitus. Current use 
of hormone therapy, calcium, and vitamin D corresponded respectively to 10.7%, 
47.7%, and 43.1% of all surveyed women. A logistic regression model was used to 
analyze the association of osteoporosis with various covariates incorporated 
into the model such as age (OR: 1.07, 95% CI: 1.05-1.09), BMI (OR: 0.92, 95% CI: 
0.89-0.96) and metformin use (OR: 0.44, 95% CI: 0.32-0.59). Metformin use, 
regardless of the presence of type 2 diabetes or obesity, was associated with a 
lower risk of osteoporosis in adult women. We propose that one explanation for 
this observation could be the effect of the drug over cellular senescence.

DOI: 10.1080/09513590.2020.1718092
PMID: 31994945 [Indexed for MEDLINE]
